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ABSTRACT 
Sarah A. Hillhouse: Effects of Kanglaite, An Anticancer Herbal 
Medicine, on Breast Cancer Cell Metabolism 
(under the direction of Dr. Yu-Dong Zhou) 
 
Kanglaite (KLT) is an anticancer herbal medicine developed in China that consists of 
mainly fatty acid triglycerides from Coix lacryma-jobi L. var. mayuen (Roman.) Stapf. In 
this study, we analyzed the effects of KLT on normal versus breast cancer cell metabolism 
using the C2C12, MCF-7, and MDA-MB-231 cell lines. Each cell line was divided into 
controls (n=3), cells with 1 µM of rotenone (n=2), or cells 0.3%, 1%, and 1.72% KLT 
concentrations. Cells were cultured in serum containing regular FCS and serum containing 
charcoal-stripped FCS in order to examine the full effects of KLT on the cell. Cell energy 
phenotype assays were conducted using the Seahorse XFe96 Analyzer, which 
simultaneously measured the cellular oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). The data from the cell phenotype assay was then analyzed in 
order to determine the effect of KLT on breast cancer cell metabolism by comparing OCR 
and ECAR within and between cell lines and generating cell energy phenotypes. The 
results showed that KLT increased OCR and ECAR for C2C12 cells when cultured in 
charcoal-stripped fetal calf serum (FCS)-enriched media. The KLT increased OCR and 
ECAR in MCF-7 cells when cultured in regular FCS. The KLT increased OCR in MDA-
MB-231 cells cultured in both serums and decreased ECAR in MDA-MB-231 cells 
cultured in regular FCS-enriched media. 
	   vi	  
TABLE OF CONTENTS 
List of Tables and Figures…………………………………………………viii 
List of Abbreviations……………………………………………………......ix 
1. Introduction…………………………………………………………........1 
 1.1 Breast Cancer Background……………………………………….1 
 1.2 Metastasis………………………………………………………...2 
 1.3 Tumor Metabolism……………………………………………….5 
 1.4 Kanglaite (KLT) …………………………………………………7 
2. Effects of Kanglaite, an Anticancer Herbal Medicine, on Breast Cancer 
Cell Metabolism……………………………………………...…………….12 
 2.1 Introduction……………………………………………………...12 
 2.2 Methods………………………………………………………….15 
  2.2.1 Cell Lines and Cell Culture………………………….....15 
2.2.2 Agilent Seahorse XF Cell Energy Phenotype Test 
Assay.........................................................................................15 
  2.2.3 Statistical Analysis……………………………………...16 
 2.3 Results…………………………………………………………...17 
  2.3.1 Baseline Comparison………………………………...…17 
	   vii	  
  2.3.2 OCR Between Conditions Over Time………………….23 
  2.3.3 ECAR Between Conditions Over Time………………...28 
  2.3.4 Cell Energy Phenotype Analysis…..……………….…..33 
 2.4 Conclusion………………………………………………………38 
 2.5 Discussion……………………………………………………….40 
List of References…………………………………………………………..42 
 
 
 
 
 
 
 
 
 
 
	   viii	  
LIST OF TABLES AND FIGURES 
Figure 1. Hallmarks of cancer………………………………………………………......…3 
Figure 2. Sequential steps in the pathogenesis of cancer metastasis……………………...5 
Figure 3. The Warburg effect in cancer…………………………………………………...6 
Table 1. Clinical trials for the study of safety and efficacy of KLTi in humans.................8 
Figure 4. Chemical structure of rotenone……………………………………………......14 
Figure 5. Baseline comparison of OCR and ECAR between conditions for C2C12 cell 
line………………………………………………………………………………………..18 
Figure 6. Baseline comparison of OCR and ECAR between conditions for MCF-7 cell 
line………………………………………………………………………………………..19 
Figure 7. Baseline comparison of OCR and ECAR between conditions for MDA-MB-231 
cell line…………………………………………………………………………………...20 
Figure 8. OCR vs. time in minutes between conditions for C2C12 cell line………….....24 
Figure 9. OCR vs. time in minutes between conditions for MCF-7 cell line……...…….25 
Figure 10. OCR vs. time in minutes between conditions for MDA-MB-231 cell line…..26 
Figure 11. ECAR vs. time in minutes between conditions for C2C12 cell line………....29 
Figure 12. ECAR vs. time in minutes between conditions for MCF-7 cell line……...….30 
Figure 13. ECAR vs. time in minutes between conditions for MDA-MB-231 cell line…31 
Figure 14. Cell energy phenotype analysis of C2C12 cell line……………………….....34 
Figure 15. Cell energy phenotype analysis of MCF-7 cell line……………………….....35 
Figure 16. Cell energy phenotype analysis of MDA-MB-231cell line………………......36 
	   ix	  
LIST OF ABBREVIATIONS 
ATP  Adenosine triphosphate 
ECAR  Extracellular acidification rate 
ETC   Electron transport chain 
FCCP  Trifluoromethoxy carbonylcyanide phenylhydrazone 
 
FCS   Fetal calf serum 
KLT  Kanglaite 
KLTi  Kanglaite injection 
NADH Nicotinamide adenine dinucleotide 
 
TCA  Tricarboxylic acid 
 
TNBC  Triple-negative breast cancer 
NSCLC  Non-small-cell lung carcinoma 
OCR   Oxygen consumption rate 
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
	   1	  
CHAPTER I 
Introduction 
Sarah A. Hillhouse 
 
1.1  Breast Cancer Background 
One in eight women living in the United States will develop breast cancer in their 
lifetime.1 Breast cancer is the most common cancer among women worldwide, with 
higher incidence rates among more developed countries.2 Many factors can contribute 
to a higher risk of breast cancer, including alcohol use, obesity, late-onset menopause, 
age, and genetics.3 Breast cancer occurs when cells in the breast tissue proliferate 
uncontrollably, eventually forming large masses called tumors.1 Although early 
screening methods have improved over the past few decades, breast cancer 
prevalence has remained relatively stable since the initial increase seen when early 
screening was first developed.1 
The most effective early screening method is mammography, which is a procedure 
using X-ray photographs of the breasts to check for any abnormalities before it is 
possible to detect them in a clinical examination.2,5 This early detection is especially 
helpful for diagnosing breast cancer at early stages that have a higher survival rate 
and are, therefore, easier to treat.2 For countries with less developed health care and 
limited resources, other screening options include clinical breast examination for 
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lumps and the use of ultrasound; however, these screening options are not as effective 
as mammograms.2 
Treatment of breast cancer varies widely depending on the stage and localization 
of the cancer in the body. Often, women will have a mastectomy, which is a surgical 
removal of the breast, along with radiation therapy and a combination of drugs if the 
cancer is localized to the breast tissue.4 However, a more advanced and metastasized 
breast cancer often results in the affected women exploring other treatment options, 
such as chemotherapy with a single drug treatment plan, hormone therapy, 
immunotherapy, or targeted therapies.4 These therapies target different mechanisms 
by utilizing various drugs, such as estrogen hormone receptor blockers and 
monoclonal antibodies. Despite the wide array of therapies and treatment drugs, 
breast cancer is still highly prevalent world-wide with more than 3.1 million women 
with breast cancer in the United States as of January 2019 and an expectation of 
41,760 deaths within the year.6 Therefore, new therapies and non-traditional 
treatments need to be explored in the future. 
 
1.2  Metastasis 
Ten hallmarks of cancer, represented in Figure 1, include uncontrollable cell 
proliferation, increased signaling for cell proliferation, formation of new capillary 
networks, cell resistance to apoptosis, cells evading tumor suppressors, avoidance of 
immune destruction, tumor-promoting inflammation, genome instability, deregulating 
cellular energetics, and activation of metastasis.7 
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Figure 1. Hallmarks of Cancer. Therapeutic targets for each hallmark can be 
studied as possible treatments for cancer. Reprinted from Cell, 144, Hanahan, D., & 
Weinberg, R. A., Hallmarks of cancer: the next generation, page 646, Copyright 
(2011), with permission from Elsevier.7  
 
Metastasis is the spread and progressive growth of cells from a primary neoplasm 
to distant organs.9 This spread of cancer to distant organs is responsible for at least 
90% of cancer-associated deaths and is a highly feared aspect of cancer.10 Many 
metastatic cancers frequently spread to the specific organs.10 For instance, metastatic 
breast cancer, also called systemic or stage IV breast cancer, most frequently 
metastasizes to the lungs, bones, liver, and brain.8 This specificity in the metastasis of 
cancer to distant organs shows that metastasis is not a random process. In 1889, 
Stephen Paget proposed the “seed and soil” hypothesis stating that metastasis depends 
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on the interaction between cancer tumor cells, or the seeds, and the specific organ 
microenvironments, or the soil.9 In other words, breast cancer may not metastasize to 
particular organs because they lack the microenvironment needed for the cells to 
survive and spread, but it may metastasize to other organs containing a preferred 
microenvironment. This hypothesis still remains today and acts as a foundation for 
further studies on cancer metastasis. 
Metastasis involves a multi-step process: invasion of the cancerous cell into 
surrounding tissue, intravasation (invasion into vasculature), survival in vasculature 
and translocation to distant tissues, extravasation (escape from vasculature to distant 
tissue), survival in the microenvironment of distant tissue, and adaptation to the new 
microenvironment that facilitates proliferation and colonization into a secondary 
neoplasm.10 In order for the cancer cells to metastasize, all conditions for each step 
must be met; otherwise, the cancer will not spread.8,9 While many steps are required 
for a cancer cell to metastasize, the treatment of a metastatic cancer is very difficult to 
achieve because of the invasive nature of metastasis, as well as the various 
mechanisms behind it. 
Despite improvements in screening and advances in treatment therapies and 
surgeries, most cancer mortalities result from the invasive and progressive growth of 
metastases that are resistant to conventional therapies.11 For instance, metastatic 
cancer stem cells have been shown to have a heightened resistance to drug-induced 
death.10 Therefore, new treatment options and therapies need to be further explored 
for the treatment of metastatic cancers. 
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Figure 2. Sequential steps in the pathogenesis of cancer metastasis. Each step is 
regulated by modifications to cancer cell nucleic acids or proteins. Only cancer cells 
that fully accomplish each step (seen in number 1) will be competent metastatic cells. 
Metastasis can be blocked at any one of these sequential steps (as seen in 2-7).  
Reprinted from Nature Reviews Cancer, 3(6), Fidler, Isaiah J., The pathogenesis of 
cancer metastasis: the ‘seed and soil’ hypothesis revisited, page 456, Copyright 
(2002), with permission from Springer Nature.9 
 
1.3  Tumor Metabolism 
Cancer cells in tumors have altered metabolic pathways that facilitate energy 
production and supply the cell with precursors for the formation of macromolecules 
in order to continuously grow and survive; therefore, one strategy for developing new 
treatment therapies for cancers is to research the mechanisms for these altered 
pathways and find ways to target them.12 One major pathway that is primarily studied 
is the Warburg effect, which is illustrated in Figure 3. This pathway enhances the 
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activity of glycolysis, in order to make energy in the form of ATP.12 Consequently, 
oxidative phosphorylation is impaired, even when oxygen is present.12 Because 
glycolysis is enhanced, cancer cells tend to have an overproduction of lactate, which 
acidifies the tumor microenvironment and facilitates the production of the enzyme 
lactate dehydrogenase. This enzyme oxidizes NADH into NAD+, thereby 
maintaining glycolysis activity.12 
 
 
 
Figure 3. The Warburg effect in cancer. A normal cell’s metabolism utilizes oxidative 
phosphorylation for basic functioning in the presence of oxygen. However, a proliferating 
cancer cell’s metabolism shifts to using glycolysis for energy and the formation of 
macromolecules. Reprinted from International Journal of Biological Sciences, 11(12), 
Zhang W. et. al., Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate 
Dehydrogenase Kinases (PDKs) a Viable Anticancer Target, page 1390, Copyright 
(2019), with permission from Ivyspring International Publisher.13 
 
Glycolysis also may provide precursors for other biosynthetic pathways needed 
for cell growth by producing pyruvate, which is needed along with oxaloacetate to 
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activate the Krebs cycle.12 The Krebs cycle, also known as the TCA cycle, normally 
produces CO2, ridding the cell of carbon needed for macromolecules that could be 
used to develop cell growth.14 However, this cycle is weakened in cancer cells as 
intermediates formed during the cycle are exported and utilized for biosynthetic 
pathways to form macromolecules, such as proteins and fatty acids.12 Therefore, less 
of the final product, oxaloacetate, is created, resulting in a decrease in the activation 
of the Krebs cycle.12 As a result, more pyruvate is utilized to form lactate mentioned 
earlier instead of being incorporated into the Krebs cycle.12 
Another altered metabolic pathway that is a consequence of the Warburg effect is 
the Crabtree effect. This pathway involves the inhibition of oxidative phosphorylation 
and cellular respiration in cancer cells by the presence of glucose from increased 
glycolysis.12 This decrease in oxidative phosphorylation and oxygen consumption 
occurs because of the decrease in the use of the Krebs cycle to form the final product 
of carbon dioxide.14 Better understanding of these alternate metabolic pathways in 
cancer cells can lead to new discoveries and new targets for treatment therapies. 
 
1.4  Kanglaite (KLT) 
As the need for alternative medicines became more prevalent, a Chinese 
pharmacologist named Li Dapeng developed the drug Kanglaite, also known as KLT, 
from the seeds of a coix plant [Coix lacryma-jobi L. var. mayuen (Roman.) Stapf.]15. 
Coix seeds had been previously used in traditional Chinese medicine for a number of 
functions including the stimulation of the function of the spleen and lung and the 
treatment of symptoms for diarrhea and arthritis.16 The KLT product is a new 
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anticancer drug first approved by the Chinese government in 1995 that can be 
administered intravenously, intra-arterially, or orally.16 The injected drug, known as 
KLTi, has been administered to more than 650,000 cancer patients in China.17  
The KLTi product has been proven to have a marked inhibitory effect on malignant 
tumors.16 Studies suggest that the KLTi mechanism of action for this marked 
inhibition is as follows: inhibit tumor cells mitosis in G2/M phase, inducing tumor 
cells apoptosis, altering genetic expression of tumor cells by up-regulating FAS/Apo-
1 gene expression and down-regulating Bc1-2 gene expression, inhibition of new 
vasculature formation, counteracting cancer cachexia, and reversing tumor cell 
resistance to anticancer chemotherapeutics.16 Clinical studies of KLT have been 
conducted in China, Russia, and a current phase II clinical trial underway in the 
United States.17 Table 1 shows a few of clinical studies on KLT that verify an 
increase in therapeutic response of chemotherapy drugs when combined with KLTi, 
as well as an increase in the quality of life in the patients. 
 
Clinical 
Trial 
Target Dosage of KLTi Findings Reference 
Phase I 
(USA) 
Patients with solid 
tumors given KLTi 
to determine safety 
of the drug. 
10, 20, 30, 40, 
and 50 grams 
(or 100-500 mL 
dosages) 
KLTi reported to 
be safe and well 
tolerated. 
Maximum 
tolerated dose 
not reached. 
16, 17 
Phase I 
(Russia) 
Patients with 
NSCLC given 
KLTi for 
determination of 
safety and effects 
of the drug in 
humans. 
200 mL in a 90 
minute 
intravenous 
infusion daily for 
days 1-21 and 29-
49. 
KLTi has good 
therapeutic 
effects and 
improves 
patient’s quality 
of life. Absence 
of toxicity for 
cytotoxic agents. 
16, 17 
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Phase I 
(Russia) 
Patients with lung 
cancer given KLTi 
to determine effect 
on immune 
function. 
N/A KLTi increased 
antigens CD95 
and CD50, 
improving 
response of 
chemotherapy in 
patients. 
16, 17 
Phase II 
(USA) 
To assess safety 
and efficacy of 
KLTi+gemcitabine 
combined therapy 
in patients with 
pancreatic cancer. 
30 g/day (300 
mL/day) and 50 
g/day (500 
mL/day) via a 
central venous 
line on days 1-5, 
8-12, and 15-19 
for each 28 day 
cycle. 
Combined 
therapy had 
enhanced 
survival rates. 
Combined 
therapy with 
KLTi 30 g/day 
showed better 
results for 
survival and 
evidence for 
anti-neoplastic 
activity than the 
50g/day dose of 
KLTi. 
18 
Phase II 
(China) 
Efficacy of KLTi 
vs. chemotherapy 
in patients with 
primary lung 
carcinoma. 
N/A KLTi and 
chemotherapy 
drug had no 
significant 
difference in 
effective rate. 
KLTi had 
superior 
therapeutic 
results than 
chemotherapy. 
No adverse 
reactions in liver, 
kidney, or heart 
functions. 
16 
Phase II 
(China) 
Efficacy of KLTi 
vs. chemotherapy 
in patients with 
NSCLC. 
N/A KLTi had 
significant 
difference in 
effective rate of 
45% while 
chemotherapy 
had 22% 
effective rate. 
16 
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Phase II 
(China) 
Efficacy of KLTi 
vs. chemotherapy 
in patients with 
primary liver 
carcinoma. 
N/A KLTi and 
chemotherapy 
drug had no 
significant 
difference in 
effective rate. 
KLTi improves 
quality of life, 
symptoms, and 
immune 
functions. 
No adverse 
effects on bone 
marrow, hepatic, 
or renal 
functions. 
16 
Phase 
III 
(China) 
Combined KLTi 
treatment with 
intervention 
therapy (IT) for 
patients with 
primary liver 
carcinoma and 
primary lung 
carcinoma. 
N/A Combined 
therapy 
(KLT+IT) was 
significantly 
more effective 
than IT alone. 
16 
Phase 
III 
(China) 
Combined KLTi 
with radiotherapy 
vs. radiotherapy 
only treatments for 
carcinomas of lung, 
esophagus, 
nasopharynx, etc. 
Combined: KLT 
intravenously 
injected 100 mL 
with 200cGy 
radiotherapy 5 
days/week. 
 
Radiotherapy 
only: some radio-
dose. 
Combined 
therapy was 
significantly 
more effective 
than radiotherapy 
alone. 
16 
Phase 
III 
(China) 
To observe 
efficacy, side 
effects, and impact 
on quality of life 
by KLTi combined 
with chemotherapy 
in the treatment of 
gastric cancer 
patients. 
100 mL 
intravenously/day 
of KLTi in 
combined therapy 
group only 
 
Combined 
therapy had 
significantly 
higher response 
rate but not a 
significantly 
different clinical 
benefit rate.  
KLTi enhanced 
efficacy, reduced 
side effects of 
19 
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chemotherapy, 
and improved 
quality of life of 
patients. 
 
Table 1. Clinical trials for the study of safety and efficacy of KLTi in humans. 
Overall, KLTi has increased therapeutic effects and quality of life in patients in these 
clinical trials. No maximum tolerated dosage (MTD) of KLTi in humans has been 
established. 
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CHAPTER II 
Effects of Kanglaite, an Anticancer Herbal Medicine, on Breast 
Cancer Cell Metabolism 
Yu-Dong Zhou, Sarah A. Hillhouse, and Dale G. Nagle 
*SAH contributed to analysis of Seahorse XFe96 data 
 
2.1 Introduction 
Kanglaite (KLT), a Chinese herbal medicine, has been one of the top five 
anticancer drugs in China for the past decade.17 The KLT product is developed from coix 
seed oil into a micro-emulsion drug for intravenous use.17 This intravenous KLT drug 
(KLTi), is made up of 0.1 g coix seed oil per mL that consists of 20.8% 1,2,3-
trioleylglycerol (C57H104O6), 19.2% 2,3-dioleoyl-1-linoleylglycerol (C57H102O6), 
18.9% 1,2-dilinoleyl-3-oleylglycerol (C57H100O6), 14.8% 2-linoleyl-3-oleyl-1-
palmitoylglycerol (C55H100O6), 11.8% 2,3-dioleyl-1-palmitoylglycerol (C55H102O6), 
7.5% 1,2-dilinoleyl-3- palmitoylglycerol (C55H98O6) and 7.0% 1,2,3-trilinoleylglycerol 
(C57H98O6)
20. Over the past twenty years, this drug consisting mainly of fatty acid 
triglycerides, has been successfully used by over one million patients in multiple 
countries and has a proven effect in the treatment of many cancers.17 
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Various studies have shown that KLTi remarkably improves immune function, 
improves cachexia (a wasting syndrome) by providing high energy nutrients, increases 
efficacy and reduces toxicity of chemotherapy or radiation therapy treatment, improves 
quality of life, and improves survival in cancer patients.17 Based on studies in China, 
multiple mechanisms for the effect of KLT on cancer cells have been proposed. Some of 
these mechanisms include the inhibition of angiogenesis, the induction of cancer cell 
apoptosis, the inhibition of tumor cell mitosis, regulation of FAS/Apo-1 and Bcl-2 gene 
expression, and reversing cachexia by providing high energy nutrients.17 For our study, 
we are mostly concerned with the effect KLT on tumor cell metabolism in breast cancer 
cell lines. In the US, a pre-clinical study at Johns Hopkins University showed that KLT 
inhibited the growth of tumors from xenografted MDA-MB-231 breast cancer cells by 
over 50%.17 We propose that one significant mechanism for this reduction in tumor 
growth is caused by the introduction of fatty triglycerides from KLT, resulting in an 
altered tumor cell metabolism. 
In this study, Dr. Yu-Dong Zhou utilized the Seahorse XFe96 Analyzer to 
perform a cell energy phenotype assay measuring the OCR and ECAR simultaneously in 
living cells with control conditions (n=3), cells with 1 µM of rotenone (n=2), and cells 
with three different concentrations of KLT in both regular fetal calf serum (FCS)-
enriched and charcoal-stripped FCS-enriched media. This allowed us to study the cell 
metabolism because their cellular oxygen consumption rate (OCR) is an indicator for 
oxidative phosphorylation, while their extracellular acidification rate (ECAR) is an 
indicator for glycolysis.21 A normal myogenic cell line C2C12 acted as a model control 
system, while a human breast adenocarcinoma cell line MCF-7 and a triple-negative 
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breast cancer (TNBC) cell line MDA-MB-231 acted as model breast cancer systems.22,23 
The Seahorse Analyzer measured the OCR and ECAR both before and after the addition 
of a stressor containing Oligomycin+FCCP. Oligomycin and FCCP are compounds that 
disrupt oxidative phosphorylation in cells by inhibiting ATP synthase or by acting as a 
protonophoric uncoupler that dissipates the mitochondrial proton gradient, respectively.21 
The combination of these compounds acts as a stressor on the cells to induce a demand 
for energy, increasing OCR and ECAR21. 
Rotenone (Figure 4) is a compound that inhibits the transfer of electrons from 
mitochondrial complex I to ubiquinone in the ETC, thus reducing the NAD oxidation and 
inhibiting cellular oxidative phosphorylation.24 Therefore, the rotenone condition (n=2) 
established a reduced cellular respiration both before and after the addition of the stressor 
compared to the normal cellular respiration seen in controls (n=3).  
 
 
 
Figure 4. Chemical Structure of Rotenone. 
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By observing the OCR and ECAR rates in each set of conditions for each cell 
line, we expected to observe a stronger increase in OCR and ECAR for cells with KLT 
after the introduction of the stressor compounds compared to cells acting as controls or 
cells containing rotenone. This would support our hypothesis that adding fat in the form 
of KLT will change cancer cell metabolism and increase cellular respiration via oxidative 
phosphorylation. 
 
2.2 Materials and Methods 
2.2.1 Cell Lines and Cell Culture 
Normal mouse myogenic C2C12 cells were purchased from ATCC and used as a 
model control cell line. Human breast cancer MCF-7 and MDA-MB-231 cells were 
purchased from ATCC and used as model breast cancer cell lines. Cells were cultured in 
DMEM/high glucose medium with 4 mM L-glutamine supplemented with 10% FCS 
[Hyclone, Cat# SH30910.03] with P/S [50 µ/mL penicillin, 50 µg streptomycin, Hyclone, 
Cat# GIBCO15140] or in DMEM/high glucose medium with 4 mM L-glutamine 
supplemented with 10% charcoal-stripped FCS [Hyclone, Cat# SH30068.02] with P/S 
[50 µg/mL penicillin, 50 µg streptomycin, Hyclone, Cat# GIBCO15140]. 
2.2.2 Agilent Seahorse XF Cell Energy Phenotype Test Assay 
The C2C12 and MDA-MB-231 cells were seeded at the density of 2000 cells/well 
and MCF-7 cells were seeded at the density of 4000 cells/well into 96-well microplates in 
a volume of 80 µL/well of either DMEM/high glucose medium with 4 mM L-glutamine 
supplemented with 10% FCS [Hyclone, Cat# SH30910.03] with P/S [50 µg/mL 
penicillin, 50 µg/mL streptomycin, Hyclone, Cat# GIBCO15140] or in DMEM/high-
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glucose medium with 4 mM L-glutamine supplemented with 10% charcoal-stripped FCS 
[Hyclone, Cat# SH3006802] with P/S [50 µg/mL penicillin, 50 µg/mL streptomycin, 
Hyclone, Cat# GIBCO15140]. Select cells in each cell line were exposed to 1 µM of 
rotenone (n=2) or KLT at 0.3%, 1%, and 1.72% concentrations. Then, the 96-well 
microplates were incubated in a humidified environment with 5% CO2 and 95% air at 
37°C for 24 hours. A sensor cartridge was hydrated in double-distilled H2O at 37°C in a 
non-CO2 incubator overnight prior to the day of the assay. 
On the day of the assay, the 96-well microplates with the cells were washed with 
XF Base Medium [1 mM pyruvate, 2 mM glutamine, 10 mM glucose] to have a total well 
volume of 180 µL. The cells were then incubated at 37°C in a non-CO2 incubator for one 
hour prior to the assay. The sensor cartridge was taken out of the water bath and placed in 
a utility plate containing 200 µL of the pre-warmed XF Calibrant. This was then 
incubated at 37°C in a non-CO2 incubator for one hour prior to assay. 
After an hour, the sensor plate was removed from the calibration plate and 20 µL 
of the stressor containing oligomycin and FCCP was injected into the port A of the 
sensory plate. The sensor plate was then loaded into the Seahorse XFe96 Analyzer along 
with the 96-well microplate containing the cells. The Seahorse XFe96 Analyzer was then 
used to calibrate the OCR and ECAR of the cells simultaneously before and after the 
stressor was added to the cells [1 µM Oligomycin, 1 µM FCCP]. 
2.2.3 Statistical Analysis 
Standard deviations were determined using Excel for all control conditions and all 
rotenone treatment conditions for each cell line in the baseline comparison of OCR and 
ECAR. 
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2.3 Results 
Control 1 was excluded from all data for the C2C12 cell line in charcoal-stripped 
FCS-enriched media because the OCR values were significantly higher than the OCR 
values in Controls 2 and 3. Control 2 was excluded from all data for the MCF-7 cell line 
in both regular and charcoal-stripped FCS-enriched media because no effect on OCR or 
ECAR was recorded after the addition of the Oligomycin+FCCP stress treatment, 
indicating the stressors were not mixed with the cells very well. All other conditions in 
the experiment were included in the following data analysis. 
2.3.1 Baseline Comparison 
Baseline measurements, obtained from the Seahorse XFe96 Analyzer, of OCR 
and ECAR for control (n=3), 1 µM of rotenone (n=2), 0.3% KLT concentration, 1% KLT 
concentration, and 1.72% KLT concentration conditions were compared in each cell line 
for both regular and charcoal-stripped FCS-enriched media before the addition of 
mitochondrial stress-inducing compounds, Oligomycin+FCCP. All baseline values were 
obtained from the third baseline measurement taken 13 minutes after the start of the cell 
energy phenotype assay. This is the last baseline measurement taken before the addition 
of stressor compounds, Oligomycin+FCCP, at 20 minutes. Standard deviations for the 
mean control condition and the mean rotenone condition for each serum in all cell lines 
are represented as error bars. 
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Figure 5. Baseline comparison of OCR and ECAR between conditions for C2C12 
cell line. A) Mean baseline OCR levels (pmol/min) for C2C12 cells with control (n=3), 
rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular FCS-enriched media. B) 
Mean baseline OCR levels (pmol/min) for C2C12 cells with control (n=2), rotenone 
(n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-stripped FCS-enriched media. 
C) Mean baseline ECAR levels (mpH/min) for C2C12 cells with control (n=3), rotenone 
(n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular FCS-enriched media. D) Mean 
baseline ECAR levels (mpH/min) for C2C12 cells with control (n=2), rotenone (n=2), 
0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-stripped FCS-enriched media. 
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Figure 6. Baseline comparison of OCR and ECAR between conditions for MCF-7 
cell line. A) Mean baseline OCR levels (pmol/min) for MCF-7 cells with control (n=2), 
rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular FCS-enriched media. B) 
Mean baseline OCR levels (pmol/min) for MCF-7 cells with control (n=2), rotenone 
(n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-stripped FCS-enriched media. 
C) Mean baseline ECAR levels (mpH/min) for MCF-7 cells with control (n=2), rotenone 
(n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular FCS-enriched media. D) Mean 
baseline ECAR levels (mpH/min) for MCF-7 cells with control (n=2), rotenone (n=2), 
0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-stripped FCS-enriched media. 
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Figure 7. Baseline comparison of OCR and ECAR between conditions for MDA-
MB-231 cell line. A) Mean baseline OCR levels (pmol/min) for MDA-MB-231 cells 
with control (n=3), rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular 
FCS-enriched media. B) Mean baseline OCR levels (pmol/min) for MDA-MB-231 with 
control (n=3), rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-stripped 
FCS-enriched media. C) Mean baseline ECAR levels (mpH/min) for MDA-MB-231 cells 
with control (n=3), rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in regular 
FCS-enriched media. D) Mean baseline ECAR levels (mpH/min) for MDA-MB-231 cells 
with control (n=3), rotenone (n=2), 0.3% KLT, 1% KLT, and 1.72% KLT in charcoal-
stripped FCS-enriched media. 
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In Figure 5A, the mean OCR baseline for C2C12 cells with control conditions 
(n=3) was similar to that of the 1% and 1.72% KLT concentration baseline OCRs, all of 
them being between 350 and 400 pmols/min. However, the 0.3% KLT concentration 
baseline OCR was fairly low at about 248 pmols/min along with the OCR baseline of the 
average rotenone conditions (n=2) at 134 pmols/min. The OCR also noticeably increased 
in cells with KLT as the concentration of KLT increased, indicating higher amounts of fat 
increases cellular respiration. In Figure 5B showing the OCR values in charcoal-stripped 
FCS-enriched media, the baseline OCR values change drastically from those in the 
regular FCS-enriched media for cells with 0.3% KLT with a new increased baseline OCR 
of 388 pmol/min and for the mean control (n=2) with a new decreased baseline OCR 
value of 183 pmol/min. Because the basal OCR values increased for cells with KLT but 
decreased for control cells in charcoal-stripped FCS-enriched media compared to cells in 
regular FCS-enriched media, this indicates that the presence of fat in the cell causes 
increased cellular respiration. The baseline ECAR values for C2C12 cells was 
represented in Figures 5C and 5D, showing similar findings to OCR between conditions 
in each serum. In other words, the condition with the highest OCR baseline value had the 
highest ECAR baseline value. Cells with rotenone (n=2) had slightly increased ECAR but 
was still the lowest compared to the other conditions. These results indicate that the 
C2C12 cell line had relatively balanced cell energy pathways by utilizing both cellular 
respiration and glycolysis for functioning. 
In Figure 6A, the highest baseline OCR value for MCF-7 cells in regular FCS-
enriched media was the OCR for cells with 1.72% KLT; however, there was no pattern of 
increase in OCR as KLT concentration was increased. Cells with rotenone (n=2) had the 
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lowest OCR as expected. In Figure 6B with MCF-7 cells in charcoal-stripped FCS-
enriched media, all conditions had lower OCR levels than in cells within the regular FCS-
enriched media in Figure 6A. The highest baseline OCR values in Figure 6B consisted of 
cells containing KLT with the highest being cells with 0.3% KLT. This indicates that 
cells with fat had higher levels of cellular respiration than in control cells (n=2). ECAR 
values represented in Figure 6C and Figure 6D show relatively high mean ECAR values 
for cells with rotenone (n=2) in both serums, indicating increased glycolysis within those 
cells. Cells with KLT for all concentrations had slightly increased, if not similar, ECAR 
values compared to the mean control ECAR (n=2) in both serums. Therefore, the addition 
of fat in MCF-7 cells may also increase glycolysis as well. 
Comparison of Figure 7A and Figure 7B shows similar results for the MDA-MB-
231 cell line with decreases in baseline OCR values for all conditions in the charcoal-
stripped FCS-enriched media compared to cells in regular FCS-enriched media with the 
cells containing some concentration of KLT having the highest OCR in both serums. 
Also, a pattern of increase in OCR as KLT concentration increased was observed in cells 
in charcoal-stripped FCS-enriched media (Figure 7B). This indicates that fat may 
increase cellular respiration within MDA-MB-231 cells. Figure 7C shows that cells with 
rotenone (n=2) in regular FCS-enriched media had the lowest ECAR and control cells 
(n=3) had the highest ECAR levels. Because the control cells had the highest rate of 
glycolysis here, this indicates that cells containing some concentration of KLT may have 
caused a very small decrease in glycolysis within the cancer cell. In Figure 7D, the 
ECAR decreased as the concentration of KLT increased within cells in charcoal-stripped 
FCS-enriched media. 
	   23	  
2.3.2 OCR Between Conditions Over Time 
Measurements of OCR in pmol/min obtained from the Seahorse XFe96 Analyzer were 
plotted over time in minutes for control (n=3), 1µM of rotenone (n=2), 0.3% KLT 
concentration, 1% KLT concentration, and 1.72% KLT concentration conditions in each 
cell line for both regular and charcoal-stripped FCS-enriched media. Baseline values of 
OCR can be seen from 0 to 20 minutes. At 20 minutes, the stressor compounds, 
Oligomycin+FCCP, were added to each well and mixed with the cells. Because these 
stressor compounds inhibit cellular respiration, a subsequent increase in OCR should be 
observed following 20 minutes as the need for cellular energy is induced.21  
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Figure 8. OCR vs. time in minutes between conditions for C2C12 cell line. A) OCR 
vs. time in minutes from C2C12 cells in regular FCS-enriched media. B) OCR vs. time in 
minutes from C2C12 cells in charcoal-stripped FCS-enriched media. 
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Figure 9. OCR vs. time in minutes between conditions for MCF-7 cell line. A) OCR 
vs. time in minutes from MCF-7 cells in regular FCS-enriched media. B) OCR vs. time in 
minutes from MCF-7 cells in charcoal-stripped FCS-enriched media. 
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Figure 10. OCR vs. time in minutes between conditions for MDA-MB-231 cell line. 
A) OCR vs. time in minutes from MDA-MB-231 cells in regular FCS-enriched media. B) 
OCR vs. time in minutes from MDA-MB-231 cells in charcoal-stripped FCS-enriched 
media. 
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decreased at 20 minutes and slowly began to increase in the time following for Controls 1 
and 3, as well as cells with KLT concentrations of 1% and 1.72%, meaning that cellular 
respiration was induced in these conditions. However, KLT concentrations of 0.3% and 
Control 2 only showed a small increase in OCR after the addition of the stressor. Figure 
8B shows how KLT at all concentrations has a higher OCR both before and after the 
addition of the stressor compared to control conditions in the charcoal-stripped FCS-
enriched media. Therefore, one could possibly infer that cells with KLT had fat that could 
act as an energy source to be utilized in cellular respiration unlike the control cells 
stripped of fat in Figure 8B. 
Figure 9A shows a marked decrease in OCR in the MCF-7 cell line after the 
addition of the stressor compounds and a slight increase thereafter in all conditions 
except rotenone. This indicates that cellular respiration was induced in cells acting as a 
control (n=2) and cells with KLT at all concentrations. However, the MCF-7 cells with 
the highest OCR both before and after the addition of the stressor were cells with 1.72% 
KLT. Figure 9B shows similar effects seen in Figure 9A; however, the baseline OCR for 
all conditions is lower in Figure 9B with charcoal-stripped FCS-enriched media 
compared to that in Figure 9A with regular FCS-enriched media. This supports the 
findings for the possible effect of fat as an energy source for altered cell metabolism and 
increased cellular respiration. 
Figure 10A shows similar effects of the stressor compounds on the OCR of 
MDA-MB-231 cells as seen in MCF-7 cells. The OCR in control cells (n=3) and cells 
with KLT at all concentrations slightly decreased until the addition of the stressor 
induced an increase in OCR after 20 minutes. In Figure 10B, cells with KLT at all 
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concentrations had a higher OCR compared to those with control conditions in the 
charcoal-stripped FCS-enriched media, further supporting the hypothesis that fat 
increases cellular respiration and alters cancer cell metabolism. 
 
2.3.3 ECAR Between Conditions Over Time 
Measurements of ECAR in mpH/min obtained from the Seahorse XFe96 Analyzer were 
plotted over time in minutes for control (n=3), 1µM of rotenone (n=2), 0.3% KLT 
concentration, 1% KLT concentration, and 1.72% KLT concentration conditions in each 
cell line for both regular and charcoal-stripped FCS-enriched media. Baseline values of 
ECAR can be seen from 0 to 20 minutes. At 20 minutes, the stressor compounds, 
Oligomycin+FCCP, were added to each well and mixed with the cells. Because these 
stressor compounds inhibit cellular respiration and induce a need for energy, an increase 
in ECAR should be observed following 20 minutes.21  
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Figure 11. ECAR vs. time in minutes between conditions for C2C12 cell line. A) 
ECAR vs. time in minutes from C2C12 cells in regular FCS-enriched media. B) ECAR 
vs. time in minutes from C2C12 cells in charcoal-stripped FCS-enriched media. 
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Figure 12. ECAR vs. time in minutes between conditions for MCF-7 cell line. A) 
ECAR vs. time in minutes from MCF-7 cells in regular FCS-enriched media. B) ECAR 
vs. time in minutes from MCF-7 cells in charcoal-stripped FCS-enriched media. 
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Figure 13. ECAR vs. time in minutes between conditions for MDA-MB-231 cell line. 
A) ECAR vs. time in minutes from MDA-MB-231 cells in regular FCS-enriched media. 
B) ECAR vs. time in minutes from MDA-MB-231 cells in charcoal-stripped FCS-
enriched media. 
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In Figure 11A and Figure 11B, the ECAR for C2C12 cells in regular FCS-
enriched media markedly increased at 20 minutes for all conditions, rotenone having a 
minimal increase, as the stressor compounds were mixed with the wells. However, the 
ECAR values slowly began to decrease in the time following for all conditions. This 
indicates that glycolysis was induced immediately after the stressor but began to decline 
as time progressed. In Figure 11A, controls 2 and 3 in the regular FCS-enriched media 
had the highest ECAR values. However, in Figure 11B, C2C12 cells with all KLT 
concentrations in the charcoal-stripped FCS-enriched media had the highest ECAR 
values immediately before and after the addition of the stressors compared to control 
cells (n=2) and cells with rotenone (n=2). Because cells containing KLT had the highest 
ECAR in charcoal-stripped FCS-enriched media and not in regular FCS-enriched media, 
it can be suggested that fat provides a source of energy for glycolysis, thereby increasing 
ECAR compared to cells without fat. 
Figure 12A and Figure 12B show a marked increase in ECAR in the MCF-7 cell 
line after the addition of the stressor compounds and a slight increase thereafter in all 
conditions except rotenone, which had an ECAR that increased after the stressor but 
stabilized soon after. This marked increase in ECAR indicates that glycolysis was 
induced by the addition of the stressor compounds in all conditions in both regular and 
charcoal-stripped FCS-enriched media. In Figure 12A, all cells with KLT had higher 
ECAR values than control cells (n=2). However, the baseline ECAR in Figure 12B for 
cells with 1.72% KLT was less than the ECAR for Control 1 after the stressor was 
introduced than in the charcoal-stripped FCS-enriched media. These results suggest that 
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introducing a small amount of fat to MCF-7 cells may increase glycolysis and a large 
amount of fat may decrease glycolysis. 
Figure 13A and Figure 13B show a steady increase of ECAR in MDA-MB-231 
cells for all conditions except rotenone from baseline to the final measurement of the cell 
phenotype assay. The ECAR in rotenone for both figure remained relatively steady both 
before and after the addition of the stressors. Control 2 had the highest ECAR values in 
both figures; however, cells with 0.3% KLT increased to match that of Control 2 by the 
last measurement in the charcoal-stripped FCS-enriched media seen in Figure 13B. This 
suggests that fat introduced to cells in low amounts may be able to act as a source of 
energy to fuel glycolysis. 
 
2.3.4 Cell Energy Phenotype Analysis 
Baseline and stressed OCR in pmol/min and ECAR in mpH/min for all conditions in both 
regular and charcoal-stripped FCS-enriched media were obtained from the Seahorse 
XFe96 Analyzer after performing a cell energy phenotype assay. These baseline and 
stressed values taken immediately before and after the addition of the stressors are 
presented below in cell energy phenotype graphs for all three cell lines. The cell energy 
phenotype assay uses the Seahorse XFe96 Analyzer to simultaneously measure OCR and 
ECAR in order to determine the energy phenotype of a cell.21 There are four different cell 
energy phenotypes including, quiescent, aerobic, glycolytic, and energetic. A quiescent 
phenotype is characteristic of a cell that is not growing because it does not use either 
oxidative phosphorylation or glycolysis very well.21 An aerobic phenotype is 
characteristic of a normal cell that is using both metabolic pathways but relies mainly on 
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oxidative phosphorylation rather than glycolysis for energy.21 A glycolytic phenotype is 
characteristic of cancer cells, which rely on glycolysis for energy.13,21 Lastly, an energetic 
phenotype indicates that the cell is utilizing both oxidative phosphorylation and 
glycolysis to gain energy.21 
 
 
Figure 14. Cell energy phenotype analysis of C2C12 cell line. A) Cell energy 
phenotype analysis of C2C12 in regular FCS-enriched media. B) Cell energy phenotype 
analysis of C2C12 in charcoal-stripped FCS-enriched media. Baseline values are 
represented by open markers. Stressed values are represented by closed markers. 
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
450.0
60.0 80.0 100.0 120.0 140.0
M
ito
ch
on
dr
ia
l	  R
es
pi
ra
tio
n
OC
R	  
(p
m
ol
/m
in
)
ECAR	  (mpH/min)
Glycolysis
A.
Control	  1
Control	  2
Control	  3
Rot	  1
Rot	  2
KLT	  0.3
KLT	  1
KLT	  1.72
Aerobic Energetic
GlycolyticQuiescent
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
60.0 80.0 100.0 120.0 140.0
M
ito
ch
on
dr
ia
l	  R
es
pi
ra
tio
n
OC
R	  
(p
m
ol
/m
in
)
ECAR	  (mpH/min)
Glycolysis
B.
Control	  2
Control	  3
Rot	  1
Rot	  2
KLT	  0.3
KLT	  1
KLT	  1.72
Aerobic Energetic
GlycolyticQuiescent
	   35	  
 
 
Figure 15. Cell energy phenotype analysis of MCF-7 cell line. A) Cell energy 
phenotype analysis of MCF-7 in regular FCS-enriched media. B) Cell energy phenotype 
analysis of MCF-7 in charcoal-stripped FCS-enriched media. Baseline values are 
represented by open markers. Stressed values are represented by closed markers. 
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Figure 16. Cell energy phenotype analysis of MDA-MB-231 cell line. A) Cell energy 
phenotype analysis of MDA-MB-231 in regular FCS-enriched media. B) Cell energy 
phenotype analysis of MDA-MB-231 in charcoal-stripped FCS-enriched media. Baseline 
values are represented by open markers. Stressed values are represented by closed 
markers. 
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In Figure 14A, controls 1 and 3, cells with rotenone (n=2), and cells with 1% 
KLT and 1.72% KLT had an aerobic phenotype at baseline but moved towards a 
glycolytic phenotype when under stress. Control 2 and cells with 0.3% KLT had less of 
an aerobic phenotype at baseline compared to controls 1 and 3, but they had a more 
energetic phenotype when under stress. In Figure 14B, all conditions moved towards a 
more glycolytic phenotype when under stress; however, all cells with KLT had the least 
glycolytic phenotype with a more aerobic or energetic phenotype than control cells (n=2) 
and cells with rotenone (n=2). 
In Figure 15A, all conditions had a more glycolytic phenotype when under stress 
than at baseline. However, cells with 1.71% KLT had the highest OCR and ECAR of all 
the other conditions, leading to less of a glycolytic phenotype. Therefore, cells with 
1.72% KLT had a higher energetic phenotype compared to controls (n=2) and cells with 
rotenone (n=2). In Figure 15B, cells with rotenone (n=2) had a more glycolytic 
phenotype when under stress than at baseline. However, the controls (n=2) and cells with 
KLT for all concentrations had an energetic phenotype when under stress with similar 
OCR and ECAR values. Because these cells had similar energetic phenotypes, no 
significant effect of KLT on the MCF-7 cells in charcoal-stripped FCS-enriched media 
can be made. 
In Figure 16A, MDA-MB-231 cells with rotenone (n=2) had a more glycolytic 
phenotype, shown in rotenone 1 condition, and a more quiescent phenotype, shown in 
rotenone 2 condition, when under stress than at baseline. Control 1, Control 3, and all 
cells with KLT slightly had a more glycolytic phenotype when under stress than at 
baseline. Control 2 was the only condition with an energetic phenotype when stressed. 
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Cells with 1% KLT had a slightly less glycolytic phenotype and a more energetic 
phenotype compared to all other conditions. In Figure 16B, MDA-MB-231 cells with 
rotenone (n=2) had a more glycolytic phenotype, shown in rotenone 1 condition, and a 
very slight increase in an energetic phenotype, shown in rotenone 2 condition, when 
under stress than at baseline. All controls (n=3) and all cells with KLT had a more 
energetic phenotype when under stress than at baseline. Cells with KLT at any 
concentration analyzed had the highest energetic phenotype of all conditions, except for 
Control 2. This is because Control 2 has a higher OCR rate while under stress than the 
other conditions for the measurement used to determine the stressed phenotype. 
However, Control 2 has a decrease in OCR immediately after this initial spike in cellular 
respiration caused by the addition of the stressor, as can be seen in Figure 10B. 
Therefore, KLT has a more energetic phenotype than controls (n=3) in MDA-MB-231 
cells. 
 
2.4 Conclusion 
Comparison of baseline OCR and ECAR measurements in each cell line and in 
each serum showed the effects of KLT on cell metabolism without a stressor in place. In 
both FCS-enriched media and charcoal-stripped FCS-enriched media, the C2C12 cell line 
showed results that indicate increased cellular respiration and glycolysis occurred as fat 
concentration in the form of KLT increased. The breast cancer MCF-7 cell line showed 
results that indicate increased cellular respiration and glycolysis occurred for cells with 
1.72% KLT compared to controls (n=2) in regular FCS-enriched media, while increased 
cellular respiration and glycolysis occurred for cells with 0.3% KLT compared to 
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controls (n=2) in charcoal-stripped FCS-enriched media. The breast cancer MDA-MB-
231 cell line showed results that indicate increased cellular respiration for all cells 
containing KLT in both serums and a decrease in glycolysis for cells containing KLT at 
all concentrations in regular FCS-enriched media and at higher concentrations in 
charcoal-stripped FCS-enriched media.  
Analyzing the OCR and ECAR over time in each cell line and in each serum 
showed the effects of KLT on cell metabolism after a stressor was introduced with OCR 
representing cellular respiration and ECAR representing glycolysis.21 The C2C12 cell 
line showed no major or outlying effect of KLT on cellular respiration compared to 
controls (n=3) in the regular FCS-enriched media but cells with KLT at all concentrations 
in charcoal-stripped FCS-enriched media had increased cellular respiration compared to 
controls (n=2). The C2C12 cell line also showed similar results for ECAR with increased 
glycolysis in cells containing KLT compared to controls (n=2) only apparent cells in the 
charcoal-stripped FCS-enriched media. The MCF-7 cell line showed increased cellular 
respiration in cells with 1.72% KLT only compared to controls (n=2) in regular FCS-
enriched media and no apparent difference in cellular respiration for cells with KLT 
compared to controls (n=2) in charcoal-stripped FCS-enriched media. The MCF-7 cell 
line also showed increased glycolysis for all cells with KLT compared to controls (n=2) 
in regular FCS-enriched media and no apparent difference in glycolysis for cells with 
KLT compared to controls (n=2) in charcoal-stripped FCS-enriched media. The MDA-
MB-231 cell line showed increased cellular respiration for cells with 1% or 1.72% KLT 
compared to controls (n=3) in regular FCS-enriched media and increased cellular 
respiration for cells with 0.3% and 1% KLT compared to controls (n=3) in charcoal-
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stripped FCS-enriched media. The MDA-MB-231 cell line also showed a decrease in 
glycolysis for cells with 0.3% KLT and 1.72% KLT compared to controls (n=3) in 
regular FCS-enriched media and no apparent difference in the rate of glycolysis for cells 
with KLT when compared to all controls (n=3) in charcoal-stripped FCS-enriched media. 
The cell energy phenotype assay showed the energy phenotypes for each 
condition within each cell line for both serums by comparing the OCR and ECAR both 
immediately before and after the stressor was introduced. The C2C12 cell line showed 
similar energy phenotypes for both cells with KLT and controls (n=3) in regular FCS-
enriched media, but the energy phenotype for all cells with KLT in the charcoal-stripped 
FCS-enriched media was less glycolytic than the controls (n=2). The MCF-7 cell line 
showed a slightly less glycolytic phenotype for cells with 1.72% KLT compared to 
controls (n=2) in regular FCS-enriched media, while both controls (n=2) and all cells 
with KLT have similar energy phenotypes in charcoal-stripped FCS-enriched media. The 
MDA-MB-231 cell line showed very little differences in energy phenotypes between 
cells with KLT and controls (n=3) in regular FCS-enriched media; however, cells with 
1% KLT had a slightly less glycolytic phenotype compared to controls (n=3) in regular 
FCS-enriched media. In charcoal-stripped FCS-enriched media, the MDA-MB-231 cells 
showed an energetic phenotype for both cells with KLT and controls (n=3) with cells 
with KLT having higher phenotypes than Controls 1 and 3. 
 
2.5 Discussion 
 Based on the data from this experiment, KLT tends to increase cellular respiration 
and glycolysis within cells. The normal myogenic C2C12 cell line acting as a control cell 
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line had a stronger balance between oxidative phosphorylation and glycolysis than the 
two breast cancer cell lines. KLT in C2C12 cells had no significant effect on cellular 
respiration or glycolysis when fat was already present in the serum. Cells with KLT in 
charcoal-stripped FCS-enriched media resulted in increases in both metabolic pathways 
for this cell line. This indicates that KLT will only benefit normal cells if they are 
deprived of fat. The breast cancer cell lines should have altered metabolism resulting in 
decreased oxidative phosphorylation, and therefore cellular respiration, and increased 
glycolysis under normal conditions.13 This increase in glycolysis and subsequent decrease 
in cellular respiration is an adaptation cancer cells evolved to obtain enough energy for 
cell proliferation, in addition to cell functioning.14 We proposed that addition of fat to 
breast cancer cells may provide a source of energy for cancer cells to utilize cellular 
respiration once more. The data presented for the MCF-7 breast cancer cell line showed 
almost no significant effects of KLT on breast cancer; however, MCF-7 cells with 1.72% 
KLT in regular FCS-enriched media increased cellular respiration and glycolysis 
compared to the controls (n=2). The majority of the data for the MDA-MB-231 breast 
cancer cell line showed increases in cellular respiration and decreases in glycolysis with 
KLT. Because KLT was shown to increase cellular respiration in both breast cancer cell 
lines, it can be inferred that fat from KLT altered the cell metabolism by providing 
another source of energy. Further study on the effects of KLT and fat on cancer cell 
metabolism needs to be explored with a focus on the different cell energy phenotypes 
between cancer cell lines.   
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